ImmunityBio (IBRX) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChart

ImmunityBio Revenue Highlights


Latest Revenue (Y)

$622.00K

Latest Revenue (Q)

$1.05M

Main Geography (Y)

Europe

ImmunityBio Revenue by Period


ImmunityBio Revenue by Year

DateRevenueChange
2023-12-31$622.00K159.17%
2022-12-31$240.00K-74.30%
2021-12-31$934.00K54.38%
2020-12-31$605.00K-72.52%
2019-12-31$2.20M4585.11%
2018-12-31$47.00K4.44%
2017-12-31$45.00K2.27%
2016-12-31$44.00K-81.36%
2015-12-31$236.00K-63.18%
2014-12-31$641.00K-

ImmunityBio generated $622.00K in revenue during NA 2023, up 159.17% compared to the previous quarter, and up 1323.40% compared to the same period a year ago.

ImmunityBio Revenue by Quarter

DateRevenueChange
2024-06-30$1.05M2517.50%
2024-03-31$40.00K-71.22%
2023-12-31$139.00K69.51%
2023-09-30$82.00K100.00%
2023-06-30$41.00K-88.61%
2023-03-31$360.00K393.15%
2022-12-31$73.00K-38.14%
2022-09-30$118.00K237.14%
2022-06-30$35.00K150.00%
2022-03-31$14.00K-96.41%
2021-12-31$390.00K490.91%
2021-09-30$66.00K-80.53%
2021-06-30$339.00K143.88%
2021-03-31$139.00K-194.56%
2020-12-31$-147.00K-197.35%
2020-09-30$151.00K-65.37%
2020-06-30$436.00K164.24%
2020-03-31$165.00K-82.07%
2019-12-31$920.00K7566.67%
2019-09-30$12.00K-29.41%
2019-06-30$17.00K240.00%
2019-03-31$5.00K-28.57%
2018-12-31$7.00K-77.42%
2018-09-30$31.00K675.00%
2018-06-30$4.00K-20.00%
2018-03-31$5.00K-58.33%
2017-12-31$12.00K50.00%
2017-09-30$8.00K-42.86%
2017-06-30$14.00K27.27%
2017-03-31$11.00K-21.43%
2016-12-31$14.00K16.67%
2016-09-30$12.00K-
2016-06-30$12.00K100.00%
2016-03-31$6.00K-57.14%
2015-12-31$14.00K40.00%
2015-09-30$10.00K-89.01%
2015-06-30$91.00K-

ImmunityBio generated $1.05M in revenue during Q2 2024, up 2517.50% compared to the previous quarter, and up 290.83% compared to the same period a year ago.

ImmunityBio Revenue Breakdown


ImmunityBio Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21
UNITED STATES$31.00K$42.00K$373.00K
Europe$591.00K$198.00K$561.00K

ImmunityBio's latest annual revenue breakdown by geography, as of Dec 23: Europe (95.02%), and UNITED STATES (4.98%).

Quarterly Revenue by Country

CountryMar 18
San Diego California$100.00K

ImmunityBio's latest quarterly revenue breakdown by geography, as of Mar 18: San Diego California (100.00%).

ImmunityBio Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
TGTXTG Therapeutics$233.66M$73.47M
MCRBSeres Therapeutics$126.33M-
ARDXArdelyx$124.46M$98.24M
VIRVir Bio$86.18M$3.08M
CVACCureVac$52.70M$12.37M
KRYSKrystal Biotech$50.70M$70.28M
BLRXBioLineRx$4.80M$6.86M
LXRXLexicon Pharmaceuticals$1.20M$1.65M
IBRXImmunityBio$622.00K$1.05M
LIFEaTyr Pharma$353.00K$235.00K
XFORX4 Pharmaceuticals-$563.00K
VKTXViking Therapeutics--
PDSBPDS Bio--
ELEVElevation Oncology--
MDGLMadrigal Pharmaceuticals-$62.17M
EFTReFFECTOR Therapeutics--

IBRX Revenue FAQ


ImmunityBio's yearly revenue for 2023 was $622K, representing an increase of 159.17% compared to 2022. The company's yearly revenue for 2022 was $240K, representing a decrease of -74.30% compared to 2021. IBRX's yearly revenue for 2021 was $934K, representing an increase of 54.38% compared to 2020.

ImmunityBio's quarterly revenue for Q2 2024 was $1.05M, a 2517.50% increase from the previous quarter (Q1 2024), and a 2453.66% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $40K, a -71.22% decrease from the previous quarter (Q4 2023), and a -88.89% decrease year-over-year (Q1 2023). IBRX's quarterly revenue for Q4 2023 was $139K, a 69.51% increase from the previous quarter (Q3 2023), and a 90.41% increase year-over-year (Q4 2022).

ImmunityBio's revenue growth rate for the last 3 years (2021-2023) was -33.40%, and for the last 5 years (2019-2023) was -71.75%.